Literature DB >> 8993266

Prolonged ischemia is associated with more pronounced rejection in the lung allograft.

C Serrick1, A Giaid, A Reis, H Shennib.   

Abstract

BACKGROUND: Previously it was found that ischemia-reperfusion injury in a left lung autotransplantation model could be a minor inducer of major histocompatibility complex (MHC) class II antigen expression. Thus, we hypothesized that prolonged ischemic times may result in increased expression of MHC class II antigens and predispose the lungs to the development of acute rejection early after transplantation.
METHODS: Twenty conditioned dogs underwent single left lung allotransplantation. Donor lungs were subjected to 4 or 24 hours (n = 10 each) of cold ischemia. Open lung biopsies, bronchoalveolar lavage fluid, and blood samples were taken preoperatively and at various intervals up to 1 week after transplantation. Lung biopsy specimens were examined histologically for MHC class II expression and graded for acute rejection. Bronchoalveolar lavage fluid and plasma were analyzed for cytokines interleukin-2 and interferon-gamma.
RESULTS: In the 4-hour ischemia group, there was mild diffuse staining of the bronchial epithelium and cellular infiltrate for MHC class II antigens after 1 week with subsequent grade 1-2 rejection. In the 24-hour ischemia group, MHC expression after 1 week revealed strong diffuse staining of bronchial epithelium, vascular endothelium, and cellular infiltrates with a significantly higher grade of rejection. Interleukin-2 and interferon-gamma significantly increased in BAL fluid early after transplantation in both groups.
CONCLUSIONS: Ischemic injury may predispose the lung allograft to the development of acute rejection, in part, through the upregulation of MHC class II antigen expression and the local release of cytokines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8993266     DOI: 10.1016/s0003-4975(96)00898-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Preservation solution supplemented with biliverdin prevents lung cold ischaemia/reperfusion injury.

Authors:  Ryujiro Sugimoto; Yugo Tanaka; Kentaro Noda; Tomohiro Kawamura; Yoshiya Toyoda; Timothy R Billiar; Kenneth R McCurry; Atsunori Nakao
Journal:  Eur J Cardiothorac Surg       Date:  2012-05-30       Impact factor: 4.191

2.  Early immunological changes associated with laryngeal transplantation in a major histocompatibility complex-matched pig model.

Authors:  E Barker; P Murison; P Macchiarini; A Jones; C Otto; H-J Rothkoetter; K Haverson; M Bailey; M Birchall; C Stokes
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 3.  Inflammation in lung transplantation for CF. Immunosuppression and modulation of inflammation.

Authors:  George B Mallory
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

4.  In the face of chronic aspiration, prolonged ischemic time exacerbates obliterative bronchiolitis in rat pulmonary allografts.

Authors:  J-C Chang; J H Leung; T Tang; M G Hartwig; Z E Holzknecht; W Parker; R D Davis; S S Lin
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

Review 5.  Inflammatory response to pulmonary ischemia-reperfusion injury.

Authors:  Calvin S H Ng; Song Wan; Ahmed A Arifi; Anthony P C Yim
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Alveolar macrophage secretory products effect type 2 pneumocytes undergoing hypoxia-reoxygenation.

Authors:  Anton S McCourtie; Alexander S Farivar; Steven M Woolley; Heather E Merry; Patrick S Wolf; Brendan Mackinnon-Patterson; John C Keech; Elizabeth Fitzsullivan; Michael S Mulligan
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

7.  Evaluation of Early Markers of Ischemia-reperfusion Injury and Preservation Solutions in a Modified Hindlimb Model of Vascularized Composite Allotransplantation.

Authors:  Sara Rostami; Michael Xu; Shaishav Datta; Siba Haykal
Journal:  Transplant Direct       Date:  2021-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.